Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial
Open Access
- 1 March 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet. Global Health
- Vol. 5 (3), e324-e334
- https://doi.org/10.1016/s2214-109x(16)30367-9
Abstract
No abstract availableKeywords
Funding Information
- Chinese Ministry of Science and Technology and the National Health and Family Planning Commission (Grant 1061400100275, 2016ZX09106003001)
This publication has 21 references indexed in Scilit:
- Ebola virus disease candidate vaccines under evaluation in clinical trialsExpert Review of Vaccines, 2016
- Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeNew England Journal of Medicine, 2016
- Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary ReportNew England Journal of Medicine, 2015
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trialThe Lancet, 2015
- Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trialThe Lancet, 2015
- An updated Ebola vaccine: immunogenic, but will it protect?The Lancet, 2015
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challengeNature Medicine, 2014
- Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus VectorClinical and Vaccine Immunology, 2010
- Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy VectorsJournal of Clinical Microbiology, 2003
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNature, 2003